Push release MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart difficulties in obese or overweight adults Semaglutide is the initial weight reduction drug accredited in britain being a preventative treatment method for those with established heart problemsWegovy® can be a weight reduction drug made up of the Energ